Bone Marrow Transplantation

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: A multicenter study

The Oncologist

Low magnesium levels and prognosis in newly diagnosed diffuse large B-cell lymphoma 

European Society for Medical Oncology (ESMO) Congress 2024 Abstract

806MO - Phase Ib study of NT-I7 (efineptakin alfa), a long-acting IL-7, post-CD19-directed CAR T cell therapy in diffuse large B-cell lymphoma (DLBCL)

Journal of Personalized Medicine

The evolving role of bispecific antibodies in diffuse large B-cell lymphoma

European Hematology Association Congress 2024 Abstract

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory diffuse large B-cell lymphoma: Results of a global randomized phase III trial (STARGLO)

New England Journal of Medicine

Combination targeted therapy in relapsed diffuse large B-cell lymphoma

Advances in Radiation Oncology

Combining obinutuzumab with radiation for refractory DLBCL: Retrospective safety and efficacy analysis

British Journal of Haematology

Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma—outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP

Cancer Medicine

Real-world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B-cell lymphoma by line of therapy

2024 ASCO Annual Meeting Abstract

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study